Another combination approach appears viable with intensive chemotherapy: inhibition of EZH2 rendered AML cells more susceptible to anthracycline-based therapy, with relatively lower anthracycline doses producing marked leukemia suppression [60]. This evidence concerns the gene EZH2 and acute myeloid leukemia.